Petrochemicals giant Ineos has agreed to buy compatriot Eastman’s Texas City site, including the 600 kt acetic acid plant and all associated third party activities on the site, for about $500 million.
Indian drugmaker Glenmark Pharma has agreed to sell 75% of the shares in its subsidiary Glenmark Life Sciences (GLS) to detergent manufacturer Nirma for 56.515 million Indian rupees (about €639.000).
Novo Holdings, controlling shareholder in drugmaker Novo Nordisk, and healthcare investment firm Gurnet Point closed their acquisition of US antibiotics specialist Paratek Pharmaceuticals in a transaction valued at $462 million. Novo Holdings said that this is its largest individual investment in antimicrobial resistance (AMR) therapies to date.
Ineos Enterprises has announced the acquisition of Eramet Titanium & Iron (ETI) from Eramet for €230 million ($245 million). The deal was completed on Sept. 21 and takes immediate effect, following the satisfaction of regulatory approvals.
Singapore-headquartered shipping company MOL Chemical Tankers has agreed to acquire the business of Fairfield Chemical Carriers, a subsidiary of Fairfield-Maxwell, in an all-cash transaction for about $400 million.
US specialty ingredients and chemicals distributor Univar Solutions has acquired Canadian company FloChem and certain of its affiliates, giving Univar access to new market segments and new service capabilities. Terms of the transaction were not disclosed.
Australian lithium miner Liontown announced that it has received a revised conditional and non-binding indicative proposal from Albemarle to acquire all of the ordinary shares outstanding in Liontown for A$3.00 in cash per share via scheme of arrangement. The revised proposal values Liontown at A$6.6 billion ($4.3 billion) on an equity value basis.
The US Federal Trade Commission (FTC) wants to clear the takeover of Irish biotech company Horizon Therapeutics by pharmaceutical group Amgen. Following concessions by Amgen, the authority is dropping its earlier objections to the $27.8 billion purchase, the FTC announced last Friday.
US science and technology group Danaher has entered into a definitive agreement to acquire Abcam, a supplier of life science research tools. Danaher will buy all of the outstanding shares of Abcam for $24.00 per share. The transaction, which is worth about $5.7 billion, is expected to close in mid-2024.
Active pharmaceutical ingredients manufacturer EuroAPI has agreed to acquire BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. Biano is to become a EuroAPI company but retain its corporate brand.
DuPont has agreed to sell an 80.1% ownership interest in the Delrin acetal homopolymer (H-POM) business to private equity company TJC in a transaction valuing the business at $1.8 billion. The transaction is expected to close around year-end 2023, subject to customary closing conditions and regulatory approval.
Thermo Fisher Scientific has completed the acquisition of CorEvitas, a provider of registry data and analytic services, from Audax Private Equity for $912.5 million in cash.
US oil and gas producer Occidental Petroleum has agreed to acquire Canadian climate solutions company Carbon Engineering for $1.1 billion, a developer of technology for large-scale direct air capture (DAC).
Danish drugmaker Novo Nordisk has agreed to acquire Montreal, Canada-based Inversago Pharma. The transaction is worth up to $1.075 billion in cash if certain development and commercial milestones are achieved, the companies said in a statement.
Swedish venture capital firm EQT is selling pharmaceutical company Schülke & Mayr to a consortium led by Athos, the family office of Hexal founders and Biontech shareholders Andreas and Thomas Strüngmann.
AkzoNobel has completed the acquisition of Sherwin-Williams’ Chinese decorative paints business, including the widely known Chinese Huarun brand.
Rotterdam-based specialty chemicals distributor IMCD has agreed to acquire 100% of the shares of Sachs Chemical, headquartered in San Juan, Puerto Rico.
Biogen and Reata Pharmaceuticals announced late last week that Biogen has agreed to acquire Reata for €156.51 per share in cash, reflecting an enterprise value of approximately €6.6 billion.
Alexion, AstraZeneca's rare disease division, has agreed to buy a portfolio of preclinical gene therapy programs and enabling technologies from competitor Pfizer for up to $1 billion, plus tiered royalties on sales.
French plant ingredients supplier Roquette, which is also is a leading player in naturally-derived pharmaceutical excipients, has agreed to acquire Qualicaps, a producer of hard capsules and pharmaceutical processing equipment for oral dosage.
SK Biopharmaceuticals, a South Korean-based biotech, has announced its new strategy to propel the company towards becoming a global “big biotech.”
Zeta, an Austrian engineering specialist for biopharmaceutical process plants, acquired a 20% share in Swiss company CB Consultancy. The transaction was completed by Jul. 14, 2023.
Major drugmaker Eli Lilly has agreed to acquire Versanis Bio, a privately held obesity drug maker, for up to $1.925 billion. The transaction is subject to customary closing conditions.
ExxonMobil has acquired Denbury, a carbon capture, utilization, and storage (CCUS) and enhanced oil recovery company. The all-stock transaction is valued at €4.5 billion.
US scientific services supplier Thermo Fisher Scientific has agreed to acquire CorEvitas, a provider of registry data and analytic services, from Audax Private Equity for $912.5 million in cash. The transaction, which is expected to be completed by the end of 2023, is subject to customary closing conditions, including regulatory approvals.
Teva Pharmaceuticals considers selling its $2 billion active pharmaceutical ingredients (API) unit as part of its "Pivot to Growth" strategy.
Solenis, a specialty chemicals manufacturer for water-intensive industries, has completed its acquisition of Diversey, a hygiene and cleaning products provider, in an all-cash transaction valued at ~ $4.6 billion.
LyondellBasell, a global leader in polymer and polyolefin technologies, has successfully acquired Mepol Group, a manufacturer of high-performing recycled compounds based in Italy and Poland.
Abcam, a biotech supplier, has garnered interest from major US life sciences companies Danaher and Agilent as it explores its potential sale. The company has also approached Germany’s Merck and attracted attention from large buyout firms, say sources of Bloomberg.
Novartis has signed an agreement to divest its 'front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company. The transaction is valued at up to $2.5 billion, which marks a strategic move to focus on innovative medicines and growth opportunities.
French specialty chemicals company Arkema plans to acquire the 54% majority stake held by Glenwood Private Equity in South Korea-listed PI Advanced Materials (PIAM) for €728 million and fully consolidate the holding. The remaining 46% of equity will continue to be listed in South Korea.
Six US states – New York, California, Illinois, Wisconsin, Minnesota and Washington – have joined the Federal Trade Commission's lawsuit to block Amgen's proposed nearly $28 billion acquisition of Horizon Therapeutics.
H.B. Fuller, which bills itself as the world’s largest pure-play adhesives provider, has announced the completion of two strategic acquisitions that it said will accelerate the transformation of the US company’s portfolio toward more highly specified applications and enhance diversification of its Construction Adhesives (CA) business.
German engineering plastics producer Covestro has rejected an initial takeover proposal from Abu Dhabi National Oil Co (ADNOC) as too low, the Bloomberg news agency reports, citing “people familiar with the matter.”
Major drugmaker Eli Lilly is to pay up to $2.4 billion to acquire Dice Therapeutics, a US biotech specializing in developing oral medicines to treat chronic autoimmune and inflammatory diseases.
